
Natera (NTRA) Stock Forecast & Price Target
Natera (NTRA) Analyst Ratings
Bulls say
Natera Inc is projected to experience significant revenue growth driven by its Signatera testing, which is expected to see increased demand in both clinical settings and global biopharmaceutical applications. The company reported a substantial quarter where it achieved a revenue beat of approximately $80 million, alongside a notable year-over-year increase of 54% in Signatera MRD volumes, translating to an addition of 21,500 tests from the previous quarter. Additionally, Natera's expansion of reimbursement coverage for its oncology tests is anticipated to enhance average selling prices and support improved gross margins and operating cash flow in the future.
Bears say
Natera has expressed concerns regarding potential margin erosion due to reductions in in-network pricing as new commercial payors begin to offer their coverage, which may expand the target addressable market but also pressure profitability. The company is also at risk from various negative developments, such as regulatory setbacks or disappointing financial performance, which could have a significant adverse impact on its stock value. Furthermore, competitive pressures from firms like Guardant Health, coupled with challenges in international expansion and reimbursement issues, add to the uncertainty surrounding Natera’s growth and financial stability.
This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares